The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: AFP and AFP-L3%, AlphaFetoprotein AFP and AFPL3
Also known as: C-Reactive Protein, CReactive Protein CRP, CRP
Also known as: CBC, CBC includes Differential and Platelets, CBC/PLT w/DIFF, Complete Blood Count (includes Differential and Platelets)
NOTE: Ulta Lab Tests provides CBC test results from Quest Diagnostics as they are reported. Often, different biomarker results are made available at different time intervals. When reporting the results, Ulta Lab Tests denotes those biomarkers not yet reported as 'pending' for every biomarker the test might report. Only biomarkers Quest Diagnostics observes are incorporated and represented in the final CBC test results provided by Ulta Lab Tests.
Also known as: Chem 12, Chemistry Panel, Chemistry Screen, CMP, Complete Metabolic Panel, Comprehensive Metabolic Panel CMP, SMA 12, SMA 20
Also known as: Gamma Glutamyl Transferase GGT, Gamma-Glutamyl Transferase, Gamma-Glutamyl Transpeptidase, Gamma-GT, GGTP, GTP
Also known as: A1c, Glycated Hemoglobin, Glycohemoglobin, Glycosylated Hemoglobin, HA1c, HbA1c, Hemoglobin A1c, Hemoglobin A1c HgbA1C, Hgb A1c
Also known as: Cholesterol, HDL,Fasting Lipids,Cholesterol, LDL, Fasting Lipids, Lipid Panel (fasting), Lipid Profile (fasting), Lipids
Also known as: Pro Time with INR, Prothrombin Time and International Normalized Ratio, Prothrombin Time PT with INR, Prothrombin Time with INR, Protime with INR, PT
The Nonalcoholic Fatty Liver Disease Advanced Assessment panel contains 10 tests with 71 biomarkers.
The Nonalcoholic Fatty Liver Disease (NAFLD) Advanced Assessment panel is a comprehensive diagnostic tool that evaluates key markers of liver health, metabolic function, and systemic inflammation. This panel offers a deeper insight into the progression and severity of NAFLD and its potential complications, such as nonalcoholic steatohepatitis (NASH), fibrosis, or hepatocellular carcinoma. By combining tests that assess liver enzymes, metabolic health, coagulation, inflammatory markers, and iron storage, the panel provides a thorough understanding of liver function and systemic effects of NAFLD, guiding healthcare providers in diagnosing, monitoring, and managing this complex condition.
The Nonalcoholic Fatty Liver Disease Advanced Assessment panel is typically ordered for individuals with known or suspected NAFLD who are at risk of disease progression or complications. It is particularly useful for patients with elevated liver enzymes, imaging findings suggestive of fatty liver, or clinical signs of advanced liver disease, such as jaundice, fatigue, or abdominal swelling. This panel may also be ordered to monitor patients with metabolic syndrome, type 2 diabetes, or obesity, as these conditions increase the risk of developing NAFLD. Additionally, it is often used to evaluate individuals who have already been diagnosed with NAFLD or NASH to assess the severity of the disease and guide treatment decisions, including determining the need for further diagnostic imaging or biopsy.
The Nonalcoholic Fatty Liver Disease Advanced Assessment panel evaluates a range of factors contributing to or affected by NAFLD, offering a multidimensional view of liver health, metabolic status, and overall systemic function.
The alpha-fetoprotein (AFP) and AFP-L3 test assesses for potential liver malignancies, such as hepatocellular carcinoma, which can develop as a complication of advanced NAFLD. Elevated levels of AFP or an increased AFP-L3 fraction can signal liver cell changes associated with cancer, making this test essential for surveillance in patients with cirrhosis or long-standing NAFLD.
The C-reactive protein (CRP) test measures levels of CRP, a marker of systemic inflammation. Chronic inflammation is a key feature of NASH and contributes to the progression of liver damage. Elevated CRP levels can indicate ongoing inflammation and may help identify patients at higher risk of developing complications related to NAFLD.
The complete blood count (CBC) with differential and platelets provides critical information about blood cell counts and platelet levels. Abnormalities in the CBC, such as low platelets, may suggest advanced liver disease or portal hypertension. Additionally, the presence of anemia or abnormal white blood cell counts can indicate complications like bleeding or infection.
The comprehensive metabolic panel (CMP) evaluates overall liver and kidney function, electrolyte balance, and metabolic health. It measures liver enzymes, bilirubin, albumin, and other key markers that indicate liver health and functionality. The CMP helps detect early liver dysfunction and assess the severity of liver injury in patients with NAFLD.
The ferritin test measures ferritin levels, reflecting iron storage in the body. Elevated ferritin levels may indicate iron overload, which is common in NAFLD and can exacerbate liver inflammation and damage. This test helps assess whether iron metabolism abnormalities are contributing to liver disease.
The gamma-glutamyl transferase (GGT) test measures GGT enzyme levels, which often rise in response to liver damage, bile duct problems, or oxidative stress. GGT is particularly useful for distinguishing NAFLD-related liver dysfunction from other causes of elevated liver enzymes.
The hemoglobin A1c (HgbA1c) test evaluates long-term blood sugar control over two to three months. Since insulin resistance is a major driver of NAFLD, this test provides insight into glucose metabolism and helps identify patients with prediabetes or diabetes, both of which increase the risk of liver complications.
The lipid panel measures cholesterol and triglyceride levels, including HDL and LDL cholesterol. Dyslipidemia is a hallmark of metabolic syndrome and contributes to the progression of NAFLD. Understanding lipid profiles helps in tailoring therapeutic interventions to manage cardiovascular risk and liver health.
The prothrombin time (PT) with INR measures blood clotting function. Prolonged PT or an elevated INR may indicate impaired liver function, as the liver produces essential clotting factors. This test helps assess the severity of liver damage and the risk of bleeding complications in patients with advanced NAFLD.
The Cardio IQ Insulin Resistance Panel with Score evaluates fasting insulin and glucose levels to calculate an insulin resistance score. Insulin resistance is central to the development and progression of NAFLD. This panel helps quantify the degree of insulin resistance and guides therapeutic strategies to improve metabolic health.
Healthcare professionals use the results of the Nonalcoholic Fatty Liver Disease Advanced Assessment panel to assess the severity and progression of NAFLD and its associated complications. For patients with elevated liver enzymes or abnormal markers, providers may confirm a diagnosis of NAFLD, evaluate the extent of liver injury, or identify potential complications, such as NASH, fibrosis, or hepatocellular carcinoma. The results also guide the need for additional diagnostic tests, such as imaging or liver biopsy, to further assess liver health.
If markers of inflammation, iron overload, or metabolic dysfunction are identified, healthcare providers may recommend targeted interventions, such as dietary changes, weight loss, medications to improve glucose and lipid metabolism, or iron reduction therapy. Abnormal clotting function or platelet counts may prompt closer monitoring or referral to a specialist for management of advanced liver disease.
The panel also helps monitor the effectiveness of therapeutic interventions. For instance, improvements in CRP levels, ferritin, or insulin resistance scores may indicate a positive response to lifestyle or pharmacological treatment. Conversely, worsening markers may signal disease progression and the need for more aggressive management strategies.
The Nonalcoholic Fatty Liver Disease Advanced Assessment panel is a vital diagnostic and monitoring tool for individuals with NAFLD, providing a detailed evaluation of liver health, metabolic status, and systemic inflammation. By identifying disease severity and associated complications, this panel helps healthcare providers implement personalized treatment plans to slow disease progression, prevent complications, and improve overall health outcomes. Its comprehensive nature underscores the importance of early detection and proactive management in addressing the challenges of NAFLD and its related metabolic and cardiovascular risks.